IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski; Makoto Nishio; Robert M. Jotte; Federico Cappuzzo; Francesco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez‐Abreu; Denis Moro‐Sibilot; Christian A. Thomas; Fabrice Barlési; Gene Grant Finley; Shengchun Kong; Anthony Lee; Shelley Coleman; Wei Zou; Mark L. McCleland; Geetha Shankar; Martin Reck

doi:10.1016/j.jtho.2021.07.009

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

At the final IMpower150 OS analysis, ACP had numerical, but not statistically significant, OS improvement versus BCP. Updated data with an additional 20 months of follow-up revealed continued OS improvement with ABCP versus BCP in all patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Socinski et al. (2021) studied this question.

synapsesocial.com/papers/6985ef823b00292770426f37 https://doi.org/10.1016/j.jtho.2021.07.009

View Full Paper

Ask AI

Bookmark

Share

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading